Multiple sclerosis drugs: Sticker shock

Annals of Neurology

Volumn 71, Issue 5, 2012, Pages

  Hauser, Stephen L ^a   Johnston, S Claiborne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LEMTRADA; NATALIZUMAB; UNCLASSIFIED DRUG;

CHRONIC LYMPHATIC LEUKEMIA; DRUG COST; EDITORIAL; HEALTH CARE COST; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE PRICING;

HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; PRESCRIPTION DRUGS;

EID: 84860177594     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23608     Document Type: Editorial

References (6)

1. Masia, Neal. "The Cost of Developing a New Drug." Focus on Intellectual Property Rights, U.S. Department of State, January 2006. Available at.
2. PRIME Therapeutics: 2011 Drug Trend Insights.
3. Huynh T,. From the Analysts Couch: The multiple sclerosis market. Nat Rev Drug Disc 2010; 9: 759.
4. Hauser SL, Johnston SC,. 4-aminopyridine: new life for an old drug. Ann Neurol 2010; 68: A8-9.
5. Eva von Schaper and Naomi Kresge Novartis's $48,000 Pill Spurs U.S. Price Increases for Older MS Treatments. Bloomberg March 21, 2011.
6. Noyes K, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis A population-based study. Neurology 2011; 77: 355-363.